- RecruitingTherapeutic confirmatory (Phase III)
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
This study looks at a new treatment called Lebrikizumab for adults and teenagers with moderate to severe eczema. We want to see how well it works and if it's safe. The main goal is to find out how many people see a big improvement in their eczema after 24 weeks.
For: Atopic DermatitisGermany · Netherlands - RecruitingTherapeutic confirmatory (Phase III)
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
This study is looking at the long-term safety and effectiveness of a new medicine called Lebrikizumab for adults and teenagers with moderate to severe eczema (atopic dermatitis). We want to see how well it works over two years and if there are any side effects.
For: Atopic DermatitisGermany · Poland - Active not recruitingPHASE3
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
This study looks at how well a new medicine, lebrikizumab, works and if it's safe for teenagers and adults with moderate to severe eczema. It wants to see if the medicine can improve skin symptoms over 24 weeks.
For: Atopic Dermatitis · EczemaGermany · Netherlands · United Kingdom - Recruiting
Molecular Signatures in Inflammatory Skin Disease
This study looks at people with skin conditions like eczema and psoriasis to understand how their bodies respond to new treatments. We want to find patterns in their genes and cells to help doctors choose the best medicine for each person in the future.
For: Atopic Dermatitis · PsoriasisGermany - Active not recruitingPHASE3
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
This study is looking into a new treatment called lebrikizumab for people with moderate to severe eczema on their hands and feet. It aims to see if it works better than a dummy treatment and how safe it is.
For: Atopic Hand and Foot DermatitisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
This study is looking into a new medicine called lebrikizumab for children and teenagers aged 6 months to 17 years who have moderate to severe eczema. We want to see how well it works, if it's safe, and how the body handles it.
For: Atopic Dermatitis · EczemaUnited States · Argentina · Australia